Pfizer, Inc. supported a study to characterize the burden of illness among adult patients with DPN receiving treatment in the US. They recruited 112 patients during routine visits at general practitioners and specialist sites who completed a one-time questionnaire that included symptom duration, out-of-pocket costs, validated pain measures, and other assessments. The full study and conclusions are available for public use. READ MORE
Source: Dovepress